Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy

Ferah Cömert Önder, Pınar Si̇yah, Serdar Durdağı, Mehmet Ay, Bülent Özpolat

RSC Medicinal Chemistry · 2022 · 19 citations · 41 references

DOIFull text

Open access

Concepts

Abstract

Eukaryotic elongation factor 2 kinase (eEF2K) has been shown to be an important molecular driver of tumorigenesis and validated as a potential novel molecular target in various solid cancers including triple negative breast cancer (TNBC).

References

41